Finding new drugs to prevent the worsening of atrial fibrillation
Project 3 Genes to Omics-Informed Drugs: Drug Repositioning and Testing to Prevent AF Progressions
This study is looking at how atrial fibrillation can get worse over time and aims to find out if any current medications can be used in new ways to help keep it from progressing, so that patients can have better treatment options.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-10896387 on NIH RePORTER |
What this research studies
This research focuses on understanding how atrial fibrillation (AF) progresses from occasional episodes to more severe forms. By investigating the genetic and molecular factors involved in AF progression, the team aims to identify existing drugs that could be repurposed to prevent this worsening. The approach combines genetic analysis with advanced algorithms to uncover the interactions between genes and environmental factors that contribute to AF. Patients may benefit from new treatment options that could help manage their condition more effectively.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with atrial fibrillation, particularly those experiencing recurrent episodes.
Not a fit: Patients with permanent atrial fibrillation who are not seeking further treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new drug therapies that prevent the progression of atrial fibrillation, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in using genetic insights to inform drug repurposing, suggesting potential success for this approach.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Chung, Mina Kay — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Chung, Mina Kay
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.